Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyaluvance is an aesthetic medical product line developed by BMG Pharma, based on its proprietary Hyaluromimethic Technology. This technology involves the covalent chemical modification of hyaluronic acid (sodium hyaluronate) on its hydroxylic groups to create biocompatible biomaterials with enhanced stability and biological properties. The product line is designed for professional aesthetic medicine, specifically for skin rejuvenation and mesotherapy. Formulations like Hyaluvance Golden combine modified hyaluronic acid with components of the extracellular matrix and regenerative activators to support skin health and provide anti-aging effects. These products are intended for cosmetic and aesthetic medicine applications rather than therapeutic disease treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hyaluvance.